gamma-aminobutyric acid has been researched along with Amyotrophic Lateral Sclerosis in 55 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We designed a phase II trial to evaluate the efficacy of gabapentin in slowing the rate of decline in muscle strength of patients with amyotrophic lateral sclerosis (ALS) and to assess safety and tolerability." | 9.08 | Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. ( Armon, C; Barohn, RJ; Bromberg, MB; Bryan, WW; Gelinas, DF; Mendoza, MC; Miller, RG; Moore, D; Neville, HE; Parry, GJ; Petajan, JH; Ravits, JM; Ringel, SP; Ross, MA; Young, LA, 1996) |
| "The release of [(3)H]D-aspartate ([(3)H]D-ASP) or [(3)H]GABA evoked by glycine from spinal cord synaptosomes was compared in mice expressing mutant human SOD1 with a Gly(93) Ala substitution ([SOD1-G93A(+)]), a transgenic model of amyotrophic lateral sclerosis, and in control mice." | 7.72 | Activation of a glycine transporter on spinal cord neurons causes enhanced glutamate release in a mouse model of amyotrophic lateral sclerosis. ( Bonanno, G; Paolucci, E; Prisco, S; Raiteri, L; Raiteri, M, 2003) |
| "To provide the biochemical rationale for the use of the new anticonvulsant agent gabapentin as a treatment for amyotrophic lateral sclerosis (ALS)." | 7.69 | Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. ( Rothstein, JD; Schielke, GP; Welty, DF, 1995) |
| "Patients with amyotrophic lateral sclerosis have increased levels of the neutrotransmitter norepinephrine in blood and cerebrospinal fluid and depressed levels of the inhibitory neurotransmitter gamma-aminobutyric acid in cerebrospinal fluid." | 7.66 | Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis. ( Brooks, BR; Enna, SJ; Lake, CR; Wood, JH; Ziegler, MG, 1980) |
| "Gabapentin is a modulator of the glutamatergic system and has been shown to prolong survival in the transgenic model of familial ALS." | 6.69 | The natural history and the effects of gabapentin in amyotrophic lateral sclerosis. ( Balzarini, C; Brigatti, M; Comazzi, F; Mazzini, L; Mora, G; Pastore, E; Pirali, I, 1998) |
| "Gabapentin was well tolerated by patients with ALS." | 6.68 | Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. ( Armon, C; Barohn, RJ; Bromberg, MB; Bryan, WW; Gelinas, DF; Mendoza, MC; Miller, RG; Moore, D; Neville, HE; Parry, GJ; Petajan, JH; Ravits, JM; Ringel, SP; Ross, MA; Young, LA, 1996) |
| "We designed a phase II trial to evaluate the efficacy of gabapentin in slowing the rate of decline in muscle strength of patients with amyotrophic lateral sclerosis (ALS) and to assess safety and tolerability." | 5.08 | Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. ( Armon, C; Barohn, RJ; Bromberg, MB; Bryan, WW; Gelinas, DF; Mendoza, MC; Miller, RG; Moore, D; Neville, HE; Parry, GJ; Petajan, JH; Ravits, JM; Ringel, SP; Ross, MA; Young, LA, 1996) |
| "The release of [(3)H]D-aspartate ([(3)H]D-ASP) or [(3)H]GABA evoked by glycine from spinal cord synaptosomes was compared in mice expressing mutant human SOD1 with a Gly(93) Ala substitution ([SOD1-G93A(+)]), a transgenic model of amyotrophic lateral sclerosis, and in control mice." | 3.72 | Activation of a glycine transporter on spinal cord neurons causes enhanced glutamate release in a mouse model of amyotrophic lateral sclerosis. ( Bonanno, G; Paolucci, E; Prisco, S; Raiteri, L; Raiteri, M, 2003) |
| "To provide the biochemical rationale for the use of the new anticonvulsant agent gabapentin as a treatment for amyotrophic lateral sclerosis (ALS)." | 3.69 | Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. ( Rothstein, JD; Schielke, GP; Welty, DF, 1995) |
| "Patients with amyotrophic lateral sclerosis have increased levels of the neutrotransmitter norepinephrine in blood and cerebrospinal fluid and depressed levels of the inhibitory neurotransmitter gamma-aminobutyric acid in cerebrospinal fluid." | 3.66 | Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis. ( Brooks, BR; Enna, SJ; Lake, CR; Wood, JH; Ziegler, MG, 1980) |
| "Gabapentin is a modulator of the glutamatergic system and has been shown to prolong survival in the transgenic model of familial ALS." | 2.69 | The natural history and the effects of gabapentin in amyotrophic lateral sclerosis. ( Balzarini, C; Brigatti, M; Comazzi, F; Mazzini, L; Mora, G; Pastore, E; Pirali, I, 1998) |
| "Gabapentin was well tolerated by patients with ALS." | 2.68 | Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. ( Armon, C; Barohn, RJ; Bromberg, MB; Bryan, WW; Gelinas, DF; Mendoza, MC; Miller, RG; Moore, D; Neville, HE; Parry, GJ; Petajan, JH; Ravits, JM; Ringel, SP; Ross, MA; Young, LA, 1996) |
| "The first clinical trials in spinal muscular atrophy are currently underway." | 2.40 | Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. ( Miller, RG, 1999) |
| " However, the dose-response curve significantly shifted toward lower concentration values in G93A motor neurons and the extent of desensitization also increased in these neurons." | 1.35 | GAB(A) receptors present higher affinity and modified subunit composition in spinal motor neurons from a genetic model of amyotrophic lateral sclerosis. ( Carunchio, I; Merlo, D; Mollinari, C; Pieri, M; Zona, C, 2008) |
| "Cramps were quite easily induced by volitional exertion and high-frequency stimulation of the peripheral nerves." | 1.29 | Muscle cramp as the result of impaired GABA function--an electrophysiological and pharmacological observation. ( Matsuoka, H; Mizoguchi, K; Nishimura, Y; Obi, T; Takatsu, M, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.45) | 18.7374 |
| 1990's | 15 (27.27) | 18.2507 |
| 2000's | 17 (30.91) | 29.6817 |
| 2010's | 17 (30.91) | 24.3611 |
| 2020's | 3 (5.45) | 2.80 |
| Authors | Studies |
|---|---|
| Kulick, D | 2 |
| Moon, E | 2 |
| Riffe, RM | 2 |
| Teicher, G | 2 |
| Van Deursen, S | 2 |
| Berson, A | 2 |
| He, W | 2 |
| Aaron, G | 2 |
| Downes, GB | 2 |
| Devoto, S | 2 |
| O'Neil, A | 2 |
| Venugopal, S | 1 |
| Ghulam-Jhelani, Z | 1 |
| Ahn, IS | 1 |
| Yang, X | 1 |
| Wiedau, M | 1 |
| Simmons, D | 1 |
| Chandler, SH | 1 |
| Blicher, JU | 1 |
| Eskildsen, SF | 1 |
| Stærmose, TG | 1 |
| Møller, AT | 1 |
| Figlewski, K | 1 |
| Near, J | 1 |
| Martin, E | 1 |
| Cazenave, W | 2 |
| Allain, AE | 2 |
| Cattaert, D | 1 |
| Branchereau, P | 2 |
| Kiernan, MC | 3 |
| Ziemann, U | 1 |
| Eisen, A | 1 |
| Caioli, S | 1 |
| Pieri, M | 2 |
| Antonini, A | 1 |
| Guglielmotti, A | 1 |
| Severini, C | 1 |
| Zona, C | 2 |
| Foerster, BR | 2 |
| Pomper, MG | 1 |
| Callaghan, BC | 2 |
| Petrou, M | 2 |
| Edden, RA | 2 |
| Mohamed, MA | 1 |
| Welsh, RC | 1 |
| Carlos, RC | 1 |
| Barker, PB | 1 |
| Feldman, EL | 2 |
| Ari, C | 1 |
| Poff, AM | 1 |
| Held, HE | 1 |
| Landon, CS | 1 |
| Goldhagen, CR | 1 |
| Mavromates, N | 1 |
| D'Agostino, DP | 1 |
| Milanese, M | 2 |
| Bonifacino, T | 2 |
| Fedele, E | 1 |
| Rebosio, C | 1 |
| Cattaneo, L | 1 |
| Benfenati, F | 1 |
| Usai, C | 2 |
| Bonanno, G | 3 |
| Medelin, M | 1 |
| Rancic, V | 1 |
| Cellot, G | 1 |
| Laishram, J | 1 |
| Veeraraghavan, P | 1 |
| Rossi, C | 1 |
| Muzio, L | 1 |
| Sivilotti, L | 1 |
| Ballerini, L | 1 |
| Diana, A | 1 |
| Pillai, R | 1 |
| Bongioanni, P | 1 |
| O'Keeffe, AG | 1 |
| Miller, RG | 6 |
| Moore, DH | 3 |
| van Zundert, B | 1 |
| Peuscher, MH | 1 |
| Hynynen, M | 1 |
| Chen, A | 1 |
| Neve, RL | 1 |
| Brown, RH | 1 |
| Constantine-Paton, M | 1 |
| Bellingham, MC | 1 |
| Carunchio, I | 1 |
| Mollinari, C | 1 |
| Merlo, D | 1 |
| Chang, Q | 1 |
| Martin, LJ | 2 |
| Rossi, S | 1 |
| De Chiara, V | 1 |
| Musella, A | 1 |
| Cozzolino, M | 1 |
| Bernardi, G | 2 |
| Maccarrone, M | 1 |
| Mercuri, NB | 1 |
| Carrì, MT | 1 |
| Centonze, D | 1 |
| Vucic, S | 1 |
| Cheah, BC | 1 |
| Ghoddoussi, F | 1 |
| Galloway, MP | 1 |
| Jambekar, A | 1 |
| Bame, M | 1 |
| Needleman, R | 1 |
| Brusilow, WS | 1 |
| Zappettini, S | 1 |
| Jacchetti, E | 1 |
| Cervetto, C | 1 |
| Sasabe, J | 1 |
| Aiso, S | 1 |
| Nieto-Gonzalez, JL | 1 |
| Moser, J | 1 |
| Lauritzen, M | 1 |
| Schmitt-John, T | 1 |
| Jensen, K | 1 |
| Le Corronc, H | 1 |
| Delpy, A | 1 |
| Meyrand, P | 1 |
| Legendre, P | 1 |
| Petri, S | 2 |
| Chenevert, TL | 1 |
| Brockington, A | 1 |
| Ning, K | 1 |
| Heath, PR | 1 |
| Wood, E | 1 |
| Kirby, J | 1 |
| Fusi, N | 1 |
| Lawrence, N | 1 |
| Wharton, SB | 1 |
| Ince, PG | 1 |
| Shaw, PJ | 1 |
| Armon, C | 2 |
| Kalra, S | 1 |
| Cashman, NR | 1 |
| Caramanos, Z | 1 |
| Genge, A | 1 |
| Arnold, DL | 1 |
| Raiteri, L | 1 |
| Paolucci, E | 1 |
| Prisco, S | 1 |
| Raiteri, M | 1 |
| Jackson, CE | 1 |
| Crochemore, C | 1 |
| Peña-Altamira, E | 1 |
| Virgili, M | 1 |
| Monti, B | 1 |
| Contestabile, A | 1 |
| Kollewe, K | 1 |
| Grothe, C | 1 |
| Hori, A | 1 |
| Dengler, R | 1 |
| Bufler, J | 1 |
| Krampfl, K | 1 |
| Wittstock, M | 1 |
| Wolters, A | 1 |
| Benecke, R | 1 |
| Niessen, HG | 1 |
| Debska-Vielhaber, G | 1 |
| Sander, K | 1 |
| Angenstein, F | 1 |
| Ludolph, AC | 1 |
| Hilfert, L | 1 |
| Willker, W | 1 |
| Leibfritz, D | 1 |
| Heinze, HJ | 1 |
| Kunz, WS | 1 |
| Vielhaber, S | 1 |
| Ziegler, MG | 1 |
| Brooks, BR | 1 |
| Lake, CR | 1 |
| Wood, JH | 1 |
| Enna, SJ | 1 |
| Obi, T | 1 |
| Mizoguchi, K | 1 |
| Matsuoka, H | 1 |
| Takatsu, M | 1 |
| Nishimura, Y | 1 |
| Cory, PR | 1 |
| Gidal, Be | 1 |
| Welty, DF | 1 |
| Schielke, GP | 1 |
| Rothstein, JD | 2 |
| Romano, JG | 1 |
| Knight, JM | 1 |
| Jones, AP | 1 |
| Redmond, JP | 1 |
| Shaw, IC | 1 |
| Moore, D | 1 |
| Young, LA | 1 |
| Barohn, RJ | 2 |
| Bromberg, MB | 1 |
| Bryan, WW | 1 |
| Gelinas, DF | 2 |
| Mendoza, MC | 1 |
| Neville, HE | 1 |
| Parry, GJ | 1 |
| Petajan, JH | 1 |
| Ravits, JM | 1 |
| Ringel, SP | 1 |
| Ross, MA | 1 |
| Gurney, ME | 1 |
| Cutting, FB | 1 |
| Zhai, P | 1 |
| Doble, A | 1 |
| Taylor, CP | 2 |
| Andrus, PK | 1 |
| Hall, ED | 1 |
| Mazzini, L | 1 |
| Mora, G | 1 |
| Balzarini, C | 1 |
| Brigatti, M | 1 |
| Pirali, I | 1 |
| Comazzi, F | 1 |
| Pastore, E | 1 |
| Niebroj-Dobosz, I | 3 |
| Janik, P | 2 |
| Forshew, DA | 1 |
| Caramia, MD | 1 |
| Palmieri, MG | 1 |
| Desiato, MT | 1 |
| Iani, C | 1 |
| Scalise, A | 1 |
| Telera, S | 1 |
| McDermott, MP | 1 |
| Rowland, LP | 1 |
| Dronsky, V | 1 |
| Mendoza, M | 1 |
| Bryan, W | 1 |
| Ravits, J | 1 |
| Yuen, E | 1 |
| Neville, H | 1 |
| Ringel, S | 1 |
| Bromberg, M | 1 |
| Petajan, J | 1 |
| Amato, AA | 1 |
| Jackson, C | 1 |
| Johnson, W | 1 |
| Mandler, R | 1 |
| Bosch, P | 1 |
| Smith, B | 1 |
| Graves, M | 1 |
| Ross, M | 1 |
| Sorenson, EJ | 1 |
| Kelkar, P | 1 |
| Parry, G | 1 |
| Olney, R | 1 |
| Brigell, MG | 1 |
| Kostera-Pruszczyk, A | 1 |
| Emeryk-Szajewska, B | 1 |
| Karwańska, A | 1 |
| Rowińska-Marcińska, K | 1 |
| Kwieciński, H | 1 |
| Kanazawa, I | 1 |
| Kuncl, RW | 1 |
| Perry, TL | 1 |
| Bergeron, C | 1 |
| Steele, JC | 1 |
| McLachlan, DR | 1 |
| Hansen, S | 1 |
| Erkman, L | 1 |
| Touzeau, G | 1 |
| Bertrand, D | 1 |
| Bader, CR | 1 |
| Kato, AC | 1 |
9 reviews available for gamma-aminobutyric acid and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Amyotrophic lateral sclerosis: Origins traced to impaired balance between neural excitation and inhibition in the neonatal period.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Brain; gamma-Aminobutyric Acid; Humans; Infant | 2019 |
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
Topics: Adult; Amyotrophic Lateral Sclerosis; Baclofen; Clinical Trials, Phase II as Topic; Clinical Trials, | 2017 |
Aberrant control of motoneuronal excitability in amyotrophic lateral sclerosis: excitatory glutamate/D-serine vs. inhibitory glycine/gamma-aminobutanoic acid (GABA).
Topics: Amyotrophic Lateral Sclerosis; Excitatory Amino Acids; gamma-Aminobutyric Acid; Glutamic Acid; Glyci | 2010 |
Maturation of the GABAergic transmission in normal and pathologic motoneurons.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Central Nervous System; Chlorides; gamma-Aminobutyric | 2011 |
How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Clinical Trials as Topic; Cyclohex | 1999 |
Potential use of gabapentin and lamotrigine.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Clinical Trials as Topic; Cyclohex | 1995 |
Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases.
Topics: Acetates; Adolescent; Adult; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrop | 1999 |
Therapeutic advances: new hope for patients with ALS.
Topics: Acetates; Aged; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; GABA Agonists; G | 1998 |
[Nerve transmitter substances and motor neuron diseases].
Topics: Acetylcholine; Adult; Amyotrophic Lateral Sclerosis; Animals; Anterior Horn Cells; gamma-Aminobutyri | 1977 |
6 trials available for gamma-aminobutyric acid and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.
Topics: Acetates; Adult; Aged; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Cyclohexanecarboxylic | 1996 |
The natural history and the effects of gabapentin in amyotrophic lateral sclerosis.
Topics: Acetates; Administration, Oral; Adult; Aged; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarbo | 1998 |
Pharmacologic reversal of cortical hyperexcitability in patients with ALS.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cerebral Cortex; Cyclohexanecarboxylic Acids; Diaze | 2000 |
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; Double-Blind Method; F | 2001 |
Motor unit hyperexcitability in amyotrophic lateral sclerosis vs amino acids acting as neurotransmitters.
Topics: Adult; Aged; Amino Acids; Amyotrophic Lateral Sclerosis; Aspartic Acid; Chromatography, High Pressur | 2002 |
Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amino Acids; Amyotrophic Lateral Sclerosis; Aspartic Acid; Chromatography, High Pressur | 2002 |
40 other studies available for gamma-aminobutyric acid and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Amyotrophic Lateral Sclerosis-Associated Persistent Organic Pollutant
Topics: Amyotrophic Lateral Sclerosis; Animals; Chlordan; gamma-Aminobutyric Acid; Humans; Motor Neurons; Ne | 2022 |
Early deficits in GABA inhibition parallels an increase in L-type Ca
Topics: Amyotrophic Lateral Sclerosis; Animals; Calcium Channels, L-Type; Disease Models, Animal; Drug Inver | 2023 |
Short echo-time Magnetic Resonance Spectroscopy in ALS, simultaneous quantification of glutamate and GABA at 3 T.
Topics: Aged; Amyotrophic Lateral Sclerosis; Aspartic Acid; Atrophy; Choline; Creatine; Disease Progression; | 2019 |
Implication of 5-HT in the Dysregulation of Chloride Homeostasis in Prenatal Spinal Motoneurons from the G93A Mouse Model of Amyotrophic Lateral Sclerosis.
Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Chlorides; Female; gamma-Aminobutyric Aci | 2020 |
Monocyte Chemoattractant Protein-1 upregulates GABA-induced current: evidence of modified GABAA subunit composition in cortical neurons from the G93A mouse model of Amyotrophic Lateral Sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Cerebral Cortex; Chemokine CCL2; Disease Mo | 2013 |
An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Case-Control Studies; Down-Regulation; Excit | 2013 |
Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model.
Topics: Amyotrophic Lateral Sclerosis; Animals; Arginine; Caprylates; Dietary Supplements; gamma-Aminobutyri | 2014 |
Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: a mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Exocytosis; Female; GABA Plasma Memb | 2015 |
Altered development in GABA co-release shapes glycinergic synaptic currents in cultured spinal slices of the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Embryo, Mammalian; Female; gamma-Ami | 2016 |
Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Newborn; Brain Stem; Disease Models, Animal; Dose-R | 2008 |
GAB(A) receptors present higher affinity and modified subunit composition in spinal motor neurons from a genetic model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Death; Cells, Cultured; Chloride Channels; Disease Mode | 2008 |
Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis mice: a quantitative confocal analysis.
Topics: Acetylcholine; Amyotrophic Lateral Sclerosis; Animals; Choline O-Acetyltransferase; Fluorescent Anti | 2009 |
Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Corpus Striatum; Disease Models, Animal; Dronabinol; Excitat | 2010 |
Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis.
Topics: Action Potentials; Adult; Aged; Amyotrophic Lateral Sclerosis; Cerebral Cortex; Electromagnetic Fiel | 2009 |
Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Corpus Striatum; Disease Models, Animal; Down-Re | 2010 |
In vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Calcium; Chelating Agents; Disease Models, Animal; Dose-Resp | 2010 |
Reduced GABAergic inhibition explains cortical hyperexcitability in the wobbler mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Immunohisto | 2011 |
Hyperexcitability and amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Female; gamma-Aminobutyric Acid; Humans; Male; Motor Cortex | 2012 |
Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Aspartic Acid; Cross-Sect | 2012 |
Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity.
Topics: Aged; Amyotrophic Lateral Sclerosis; Female; gamma-Aminobutyric Acid; Gene Expression Regulation; Ge | 2013 |
Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy.
Topics: Acetates; Aged; Amines; Amyotrophic Lateral Sclerosis; Aspartic Acid; Cell Survival; Creatine; Cyclo | 2003 |
Activation of a glycine transporter on spinal cord neurons causes enhanced glutamate release in a mouse model of amyotrophic lateral sclerosis.
Topics: Age Factors; Amino Acid Transport Systems, Neutral; Amyotrophic Lateral Sclerosis; Animals; D-Aspart | 2003 |
Western ALS Study Group.
Topics: Amines; Amyotrophic Lateral Sclerosis; Calcium Channel Blockers; Ciliary Neurotrophic Factor; Clinic | 2004 |
Disease-related regressive alterations of forebrain cholinergic system in SOD1 mutant transgenic mice.
Topics: Acetylcholine; Amyotrophic Lateral Sclerosis; Animals; Basal Nucleus of Meynert; Brain Stem; Cerebra | 2005 |
GABA(A)-receptor mRNA expression in the prefrontal and temporal cortex of ALS patients.
Topics: Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Biomarkers; Down-Regulation; gamma-Aminobuty | 2006 |
Transcallosal inhibition in amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Corpus Callosum; Evoked Potentials, Motor; Female; gamma-Aminob | 2007 |
Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Aspartic Acid; Disease Mo | 2007 |
Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis.
Topics: Adult; Amyotrophic Lateral Sclerosis; Female; gamma-Aminobutyric Acid; Humans; Male; Muscular Diseas | 1980 |
Muscle cramp as the result of impaired GABA function--an electrophysiological and pharmacological observation.
Topics: Amyotrophic Lateral Sclerosis; Baclofen; Clomipramine; Diazepam; Electric Stimulation; Evoked Potent | 1993 |
Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis.
Topics: Acetates; Amines; Amino Acids, Branched-Chain; Amyotrophic Lateral Sclerosis; Anticonvulsants; Brain | 1995 |
Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Cyclohexanecarboxylic Acids; Fasci | 1996 |
Identification of brain metabolites by magnetic resonance spectroscopy in MND/ALS.
Topics: Amyotrophic Lateral Sclerosis; Aspartic Acid; Brain; Brain Chemistry; Creatine; gamma-Aminobutyric A | 1996 |
Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain; Cyclohexanecarboxylic Acids; Diet; | 1996 |
New approaches to therapy of amyotrophic lateral sclerosis.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrophic Factor; Cyclohe | 1998 |
Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS).
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Aspartic Acid; Brain; Cell Death; Chromatography, High P | 1999 |
ALS defeats gabapentin: reflections on another failed treatment.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2001 |
ALS defeats gabapentin: reflections on another failed treatment.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; Excitatory Amino Acid | 2001 |
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.
Topics: Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biological Transport; Brain; Female; gamma-A | 1992 |
Brain amino acid contents are dissimilar in sporadic and Guamanian amyotrophic lateral sclerosis.
Topics: Aged; Amino Acids; Amyotrophic Lateral Sclerosis; Brain; Female; gamma-Aminobutyric Acid; Glutamates | 1990 |
Characterization of dissociated monolayer cultures of human spinal cord.
Topics: Acetylcholine; Amyotrophic Lateral Sclerosis; Blood Proteins; Cell Survival; Cells, Cultured; Cholin | 1989 |